New Republic Capital LLC Makes New $179,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

New Republic Capital LLC purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 26,471 shares of the company’s stock, valued at approximately $179,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Axxcess Wealth Management LLC grew its position in Recursion Pharmaceuticals by 4.3% in the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after buying an additional 1,795 shares during the last quarter. Wedmont Private Capital grew its holdings in shares of Recursion Pharmaceuticals by 10.6% in the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after acquiring an additional 2,000 shares during the last quarter. Green Alpha Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 3.6% during the fourth quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock worth $454,000 after purchasing an additional 2,346 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Recursion Pharmaceuticals by 5.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock valued at $346,000 after purchasing an additional 2,667 shares during the last quarter. Finally, KBC Group NV boosted its position in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 0.1 %

Shares of Recursion Pharmaceuticals stock opened at $7.66 on Wednesday. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The company has a market cap of $2.99 billion, a P/E ratio of -5.01 and a beta of 0.86. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $7.16 and a 200 day moving average price of $6.88.

Analyst Ratings Changes

RXRX has been the topic of several recent analyst reports. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.